



NEWS RELEASE

## Viridian Therapeutics to Present at Upcoming Investor Conferences

11/3/2021

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Credit Suisse 30th Annual Healthcare Conference and participate in fireside chats at the Jefferies London Healthcare Conference and the Evercore ISI 4th Annual HealthCONx Conference.

---

Credit Suisse 30 th Annual Healthcare Conference  
Format: Corporate Presentation  
Date: Monday, November 8, 2021  
Time: 8:50am EST

Jefferies London Healthcare Conference  
Format: Fireside Chat  
Date: Thursday, November 18, 2021  
Time: 8:00am GMT

**Webcast Link**

Evercore ISI 4 th Annual HealthCONx Conference  
Format: Fireside Chat  
Date: Wednesday, December 1, 2021  
Time: 10:55am EST

**Webcast Link**

### About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies. Viridian's most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated

target for the treatment of thyroid eye disease (TED). TED is a debilitating auto immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.

Viridian Contacts:

Investors:

Dan Ferry

LifeSci Advisors

617-430-7576

**IR@viridiantherapeutics.com**

Media:

Darby Pearson

Verge Scientific Communications

703-587-0831

**PR@viridiantherapeutics.com**

Source: Viridian Therapeutics, Inc.